Total Payments
$482,996
2024 Payments
$5,272
Companies
19
Transactions
389
Medicare Patients
1,209
Medicare Billing
$1.8M
Payment Breakdown by Category
Other$336,611 (69.7%)
Consulting$116,575 (24.1%)
Travel$19,825 (4.1%)
Food & Beverage$9,931 (2.1%)
Education$53.50 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $327,911 | 103 | 67.9% |
| Consulting Fee | $116,575 | 28 | 24.1% |
| Travel and Lodging | $19,825 | 79 | 4.1% |
| Food and Beverage | $9,931 | 175 | 2.1% |
| Honoraria | $8,700 | 3 | 1.8% |
| Education | $53.50 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $139,270 | 102 | $0 (2019) |
| Genentech USA, Inc. | $100,924 | 79 | $0 (2022) |
| Biogen, Inc. | $79,792 | 59 | $0 (2019) |
| EMD Serono, Inc. | $45,881 | 42 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $40,658 | 36 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $20,763 | 2 | $0 (2020) |
| Acorda Therapeutics, Inc | $11,628 | 11 | $0 (2018) |
| Celgene Corporation | $9,619 | 8 | $0 (2021) |
| Teva Pharmaceuticals USA, Inc. | $9,017 | 9 | $0 (2017) |
| Horizon Therapeutics plc | $8,808 | 10 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $5,272 | 7 | Amgen Inc. ($3,558) |
| 2023 | $12,807 | 13 | Horizon Therapeutics plc ($7,058) |
| 2022 | $12,875 | 8 | Genentech USA, Inc. ($9,365) |
| 2021 | $2,340 | 2 | Celgene Corporation ($1,440) |
| 2020 | $6,498 | 4 | EMD Serono, Inc. ($4,300) |
| 2019 | $120,299 | 101 | GENZYME CORPORATION ($36,430) |
| 2018 | $173,636 | 142 | GENZYME CORPORATION ($55,885) |
| 2017 | $149,269 | 112 | GENZYME CORPORATION ($46,955) |
All Payment Transactions
389 individual payment records from CMS Open Payments — Page 1 of 16
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/08/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | Cash or cash equivalent | $135.30 | General |
| Category: Inflammation/Rare Disease | ||||||
| 10/08/2024 | Amgen Inc. | UPLIZNA (Biological) | Travel and Lodging | Cash or cash equivalent | $68.70 | General |
| Category: Inflammation/Rare Disease | ||||||
| 10/01/2024 | Amgen Inc. | UPLIZNA (Biological) | Consulting Fee | Cash or cash equivalent | $3,300.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 09/25/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Consulting Fee | Cash or cash equivalent | $1,688.00 | General |
| Category: Immunology | ||||||
| 09/16/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $31.66 | General |
| Category: Inflammation/Rare Disease | ||||||
| 09/16/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $21.88 | General |
| Category: Inflammation/Rare Disease | ||||||
| 05/07/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $26.09 | General |
| 12/12/2023 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Consulting Fee | Cash or cash equivalent | $900.00 | General |
| Category: Immunology | ||||||
| 09/30/2023 | Horizon Therapeutics plc | UPLIZNA (Drug) | Honoraria | Cash or cash equivalent | $6,050.00 | General |
| Category: UPLIZNA | ||||||
| 09/30/2023 | Horizon Therapeutics plc | UPLIZNA (Drug) | Travel and Lodging | Cash or cash equivalent | $350.00 | General |
| Category: UPLIZNA | ||||||
| 09/30/2023 | Horizon Therapeutics plc | UPLIZNA (Drug) | Travel and Lodging | Cash or cash equivalent | $243.93 | General |
| Category: UPLIZNA | ||||||
| 09/30/2023 | Horizon Therapeutics plc | UPLIZNA (Drug) | Travel and Lodging | Cash or cash equivalent | $171.54 | General |
| Category: UPLIZNA | ||||||
| 09/30/2023 | Horizon Therapeutics plc | UPLIZNA (Drug) | Travel and Lodging | Cash or cash equivalent | $77.19 | General |
| Category: UPLIZNA | ||||||
| 09/30/2023 | Horizon Therapeutics plc | UPLIZNA (Drug) | Food and Beverage | In-kind items and services | $65.00 | General |
| Category: UPLIZNA | ||||||
| 09/30/2023 | Horizon Therapeutics plc | UPLIZNA (Drug) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: UPLIZNA | ||||||
| 09/30/2023 | Horizon Therapeutics plc | UPLIZNA (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: UPLIZNA | ||||||
| 09/30/2023 | Horizon Therapeutics plc | UPLIZNA (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: UPLIZNA | ||||||
| 04/24/2023 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | Consulting Fee | Cash or cash equivalent | $3,450.00 | General |
| Category: Immunology | ||||||
| 04/24/2023 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | Food and Beverage | In-kind items and services | $99.00 | General |
| Category: Immunology | ||||||
| 01/20/2023 | CYCLE PHARMACEUTICALS INC | NITYR (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,300.00 | General |
| Category: Gastrointestinal | ||||||
| 12/02/2022 | Genentech USA, Inc. | Enspryng (Biological) | Food and Beverage | In-kind items and services | $120.81 | General |
| Category: Immunology | ||||||
| 12/01/2022 | Genentech USA, Inc. | Enspryng (Biological) | Consulting Fee | Cash or cash equivalent | $7,760.00 | General |
| Category: Immunology | ||||||
| 12/01/2022 | Genentech USA, Inc. | Enspryng (Biological) | Travel and Lodging | In-kind items and services | $945.66 | General |
| Category: Immunology | ||||||
| 12/01/2022 | Genentech USA, Inc. | Enspryng (Biological) | Travel and Lodging | Cash or cash equivalent | $218.01 | General |
| Category: Immunology | ||||||
| 12/01/2022 | Genentech USA, Inc. | Enspryng (Biological) | Travel and Lodging | In-kind items and services | $200.00 | General |
| Category: Immunology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 192 | 434 | $86,925 | $23,436 |
| 2022 | 11 | 279 | 12,606 | $1.4M | $539,567 |
| 2021 | 15 | 363 | 15,628 | $1.8M | $676,054 |
| 2020 | 13 | 375 | 12,961 | $1.3M | $513,710 |
Total Patients
1,209
Total Services
41,629
Medicare Billing
$1.8M
Procedure Codes
48
All Medicare Procedures & Services
48 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 72 | 94 | $30,268 | $8,190 | 27.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 38 | 45 | $19,395 | $6,134 | 31.6% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 12 | 60 | $13,140 | $3,163 | 24.1% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 13 | 21 | $9,135 | $2,048 | 22.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 11 | 11 | $6,655 | $1,826 | 27.4% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 11 | 11 | $4,345 | $1,150 | 26.5% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 13 | 26 | $2,392 | $555.12 | 23.2% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 11 | 16 | $1,520 | $355.80 | 23.4% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 11 | 150 | $75.00 | $13.71 | 18.3% |
| J2350 | Injection, ocrelizumab, 1 mg | Office | 2022 | 13 | 12,000 | $1.3M | $512,749 | 38.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 85 | 101 | $32,522 | $8,464 | 26.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 39 | 51 | $21,981 | $6,739 | 30.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 20 | 20 | $12,100 | $3,470 | 28.7% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 19 | 30 | $13,050 | $2,891 | 22.2% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 23 | 23 | $9,085 | $2,530 | 27.8% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 13 | 25 | $2,825 | $789.56 | 27.9% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2022 | 19 | 35 | $3,220 | $745.45 | 23.2% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2022 | 19 | 30 | $2,850 | $685.10 | 24.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 11 | 11 | $2,431 | $479.96 | 19.7% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2022 | 18 | 280 | $140.00 | $24.67 | 17.6% |
| J2350 | Injection, ocrelizumab, 1 mg | Office | 2021 | 17 | 14,701 | $1.6M | $636,634 | 39.4% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2021 | 33 | 79 | $34,365 | $8,952 | 26.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 47 | 62 | $26,722 | $8,042 | 30.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 72 | 88 | $28,336 | $7,826 | 27.6% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 18 | 18 | $10,890 | $3,175 | 29.2% |
About Dr. Syed Rizvi, MD
Dr. Syed Rizvi, MD is a Neurology healthcare provider based in Providence, Rhode Island. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/29/2006. The National Provider Identifier (NPI) number assigned to this provider is 1770511446.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Syed Rizvi, MD has received a total of $482,996 in payments from pharmaceutical and medical device companies, with $5,272 received in 2024. These payments were reported across 389 transactions from 19 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($327,911).
As a Medicare-enrolled provider, Rizvi has provided services to 1,209 Medicare beneficiaries, totaling 41,629 services with total Medicare billing of $1.8M. Data is available for 4 years (2020–2023), covering 48 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Providence, RI
- Active Since 06/29/2006
- Last Updated 12/18/2025
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1770511446
Products in Payments
- LEMTRADA (Drug) $97,248
- OCREVUS (Biological) $53,945
- AUBAGIO (Drug) $49,826
- TYSABRI (Biological) $45,702
- GILENYA (Drug) $31,888
- Mavenclad (Biological) $29,747
- Non-Covered Product (Drug) $27,118
- DISEASE STATE (Drug) $12,946
- AMPYRA (Drug) $11,628
- TECFIDERA (Drug) $11,307
- Rebif (Biological) $9,429
- Enspryng (Biological) $9,365
- COPAXONE (Drug) $9,017
- UPLIZNA (Drug) $8,808
- MAYZENT (Drug) $8,018
- Ozanimod (Drug) $7,795
- SOLIRIS (Drug) $4,429
- Mavenclad (Drug) $4,300
- UPLIZNA (Biological) $3,558
- Ocrevus (Biological) $3,549
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Providence
Stephen Salloway, Md, MD
Neurology — Payments: $323,920
Neurology $323,920
J Easton, Md, MD
Neurology — Payments: $274,886
Neurology $274,886
Jeffrey Wishik, Md, MD
Neurology — Payments: $46,542
Neurology $46,542
Dr. Karen Furie, Md, MD
Neurology — Payments: $31,250
Neurology $31,250
Dr. Chuang-Kuo Wu, M.d., Phd, M.D., PHD
Neurology — Payments: $27,531
Neurology $27,531
Joseph Friedman, Md, MD
Neurology — Payments: $18,203
Neurology $18,203